Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy (based on a review of medical history and physical examination) based on the clinical judgment of the investigator~* Male or female approximately 2 months of age, from 42 days to 90 days inclusive, at the time of obtaining the informed consent~* Have a legally acceptable representative who understands the study procedures, alternate treatments available, and risks involved with the study and voluntarily agrees to participate by giving written informed consent.~Exclusion Criteria:~* History of Invasive Pneumococcal Disease (IPD) (positive blood culture, positive cerebrospinal fluid culture, or other sterile site) or known history of other culture positive pneumococcal disease~* Known hypersensitivity to any component of the pneumococcal conjugate vaccine (PCV) or any diphtheria toxoid containing vaccine~* Known or suspected impairment of immunological function~* History of congenital or acquired immunodeficiency~* Has or his/her mother has a documented human immunodeficiency virus (HIV) infection~* Known or history of functional or anatomic asplenia~* Failure to thrive based on the clinical judgment of the investigator~* Known coagulation disorder contraindicating intramuscular vaccination~* History of autoimmune disease (including but not limited to systemic lupus erythematosus, antiphospholipid syndrome, Behcet's disease, autoimmune thyroid disease, polymyositis and dermatomyositis, scleroderma, type 1 diabetes mellitus, or other autoimmune disorders)~* Known neurologic or cognitive behavioral disorder, including encephalitis/myelitis, acute disseminating encephalomyelitis, pervasive development disorder, and related disorders~* Received a dose of any pneumococcal vaccine prior to study entry~* Received a blood transfusion or blood products, including immunoglobulins, before receipt of first dose of study vaccine~* Participated in another clinical study of an investigational product before the beginning or anytime during the duration of the current clinical study. Participants enrolled in observational studies may be included.~* Has any other reason that, in the opinion of the investigator, may interfere with the evaluation required by the study~* Has an immediate family member who is investigational site or Sponsor staff directly involved with this study.

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 90 Days
- Healthy Volunteers: t

Study Arms:
- V114 (Type: EXPERIMENTAL): Participants will receive a single 0.5 mL intramuscular (IM) injection of V114 at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).
- Prevnar 13™ (Type: ACTIVE_COMPARATOR): Participants will receive a single 0.5 mL IM injection of Prevnar 13™ at approximately 2 months of age (Vaccination 1); approximately 4 months of age (Vaccination 2); approximately 6 months of age (Vaccination 3); and approximately 12-15 months of age (Vaccination 4).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete